연구성과로 돌아가기

2020 연구성과별 연구자 정보 (1641 / 2428)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Ahn, J. B. Ahn, JB 7 Severance Hosp, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Lee, M. A. Lee, MA 8 Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Lin, J. Lin, J 9 Mackay Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Taipei, Taiwan
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Ho, G. F. Ho, GF 10 Univ Malaya, Med Ctr, Clin Oncol Unit, Kuala Lumpur, Malaysia B-8634-2010 HO, GWO FUANG 0000-0002-2620-9174 Ho, Gwo Fuang
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Anh, L. T. Anh, LT 11 Cho Ray Hosp, Med Oncol, Ho Chi Minh City, Vietnam
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Temraz, S. Temraz, S 12 Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Burge, M. Burge, M 13 Royal Brisbane Hosp, Dept Med Oncol, Brisbane, Qld, Australia
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Chua, C. Chua, C 14 Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Huang, J. Huang, J 15 Merck Pte Ltd, Oncol, Singapore, Singapore
Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study Park, Y. S. Park, YS 16 Samsung Med Ctr, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
Protection against UVB-Induced Photoaging by Nypa fruticans via Inhibition of MAPK/AP-1/MMP-1 Signaling Choi, Hee-Jeong Choi, HJ 1 Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea sang@knu.ac.kr;
Protection against UVB-Induced Photoaging by Nypa fruticans via Inhibition of MAPK/AP-1/MMP-1 Signaling Alam, Md Badrul Alam, MB 2 Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea AAK-7176-2021 Alam, Md Badrul sang@knu.ac.kr;
Protection against UVB-Induced Photoaging by Nypa fruticans via Inhibition of MAPK/AP-1/MMP-1 Signaling Alam, Md Badrul Alam, MB 2 Kyungpook Natl Univ, Inner Beauty Antiaging Ctr, Food & Bioind Res Inst, Daegu 41566, South Korea AAK-7176-2021 Alam, Md Badrul sang@knu.ac.kr;
Protection against UVB-Induced Photoaging by Nypa fruticans via Inhibition of MAPK/AP-1/MMP-1 Signaling Baek, Mi-Eun Baek, ME 3 Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea sang@knu.ac.kr;
Protection against UVB-Induced Photoaging by Nypa fruticans via Inhibition of MAPK/AP-1/MMP-1 Signaling Kwon, Yoon-Gyung Kwon, YG 4 Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea sang@knu.ac.kr;
페이지 이동: